Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 66, Issue 3, Pages 409-415Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2010.12.025
Keywords
CD2-binding protein 1/proline-serine-threonine-phosphatase-interactive protein 1; inflammatory skin disease; interleukin-1 beta; interleukin-1 receptor antagonist; neutrophilic dermatitis; pyogenic arthritis
Categories
Ask authors/readers for more resources
Background: PAPA syndrome is a recently identified hereditary autoinflammatory syndrome clinically characterized by pyogenic arthritis, severe acne, and pyoderma gangrenosum. It is caused by mutations in the PSTPIP1 gene and may be closely linked to the aseptic abscesses syndrome, which has been shown to be associated with CCTG repeat amplification in the promoter region of PSTPIP1. Objective: We describe two unrelated patients with a clinical presentation quite similar to, yet distinct from, PAPA syndrome. Results: Both patients had pyoderma gangrenosum and acute or remittent acne conglobata, but, in contrast to PAPA syndrome, lacked any episodes of pyogenic arthritis. Instead, they had suppurative hidradenitis. Mutations in PSTPIP1 exons 1 to 15 were excluded. In the promoter region, an increased repetition of the CCTG microsatellite motif was present on one allele in both patients. Alterations of the most commonly affected exons of the MEFV, NLRP3, and TNFRSF1A genes also were not detectable. One patient was treated with the interleukin (IL)-1 receptor antagonist anakinra and responded well, although without complete remission. This implies that IL-1 beta may be of pathogenetic importance. Limitations: Small number of patients, no gene mutation identified, and unclear efficacy of therapy are limitations. Conclusions: The clinical triad of pyoderma gangrenosum, acne, and suppurative hidradenitis represents a new disease entity within the spectrum of autoinflammatory syndromes, similar to PAPA and aseptic abscesses syndrome. For this disease, we propose the acronym PASH'' syndrome. PASH syndrome may respond to IL-1 beta blockade. (J Am Acad Dermatol 2012;66:409-15.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available